Find a Product

CAL-101 (Idelalisib, GS-1101)

CAL-101 (Idelalisib, GS-1101, Zydelig) is a synthetic drug that potently inhibits the phosphoinositide 3-kinase P110δ (IC50=2.5nM), with 40-300-fold selectivity over p110α, β, and γ. FDA approved for treatment of chronic lymphocytic leukemia (CLL) in combination with rituximab.

Catalog No. Size Price Quantity
92-1258 10 mg $235.00

For account specific pricing, please contact Customer Service at
CAL-101 (Idelalisib, GS-1101)
Compound Type
Cells were plated in a 384-well plate and incubated overnight at 37°C/5% CO₂ to allow the cells to attach and grow. Cells were then stimulated with a control compound, using the assay conditions described below. Following treatment, signal was detected using the InCELL Hunter Detection Kit according to the recommended protocol.